Official
RtR
1-6-03

Docket No.: 44033-080

PATENT

#24C
PS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

J. Peter Klein, et al.

HANDCARRIED TO T.C. 1600

Application No.: 09/288,556

Group Art Unit: 1624

Filed: April 9, 1999

Examiner: R. Raymond

For: THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME

SUPPLEMENTAL AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This is a supplemental response to the non-final Office Action dated September 16, 2002.

Please amend the above-identified patent application as set forth below.

Please amend claims 1, 3 and 22-25 to read as follows:

1. (Four Times Amended) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula (I):



I

Ct Sub D1

wherein:

X and Y are N or N(R_3);

Z is C(R_4);

R_1 is selected from a member of the group consisting of hydrogen, methyl, $C_{(5-9)}$alkyl, $C_{(5-9)}$alkenyl, $C_{(5-9)}$alkynyl, $C_{(5-9)}$hydroxyalkyl, $C_{(3-8)}$alkoxyl, $C_{(5-9)}$alkoxyalkyl, the R_1 being optionally substituted;

R_2 and R_3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, $C_{(1-20)}$alkyl, $C_{(1-20)}$hydroxyalkyl, $C_{(1-20)}$thioalkyl, $C_{(1-20)}$alkylamino, $C_{(1-20)}$alkylaminoalkyl, $C_{(1-20)}$aminoalkyl, $C_{(1-20)}$aminoalkoxyalkenyl, $C_{(1-20)}$aminoalkoxyalkynyl, $C_{(1-20)}$diaminoalkyl, $C_{(1-20)}$triaminoalkyl, $C_{(2-20)}$tetraaminoalkyl, $C_{(5-15)}$aminotrialkoxyamino, $C_{(1-20)}$alkylamido, $C_{(1-20)}$alkylamidoalkyl, $C_{(1-20)}$amidoalkyl, $C_{(1-20)}$acetamidoalkyl, $C_{(1-20)}$alkenyl, $C_{(1-20)}$alkynyl, $C_{(3-8)}$alkoxyl, $C_{(1-11)}$alkoxyalkyl, and $C_{(1-20)}$dialkoxyalkyl;

R_4 is selected from a member of the group consisting of hydrogen, halo, oxo, $C_{(1-20)}$alkyl, $C_{(1-20)}$hydroxyalkyl, $C_{(1-20)}$thioalkyl, $C_{(1-20)}$alkylamino, dialkylamino, $C_{(1-20)}$alkylaminoalkyl, $C_{(1-20)}$aminoalkyl, $C_{(1-20)}$aminoalkoxyalkenyl, $C_{(1-20)}$aminoalkoxyalkynyl, $C_{(1-20)}$diaminoalkyl, $C_{(1-20)}$triaminoalkyl, $C_{(2-20)}$tetraaminoalkyl, $C_{(5-15)}$aminotrialkoxyamino, $C_{(1-20)}$alkylamido, $C_{(1-20)}$alkylamidoalkyl, $C_{(1-20)}$amidoalkyl, $C_{(1-20)}$acetamidoalkyl, $C_{(1-20)}$alkenyl, $C_{(1-20)}$alkynyl, $C_{(3-8)}$alkoxyl, $C_{(1-11)}$alkoxyalkyl, and $C_{(1-20)}$dialkoxyalkyl; and

— - — - represents a double or single bond;

with the proviso that R_1 is not an ω-1-hydroxyalkyl group having from 5 to 9 carbon atoms when R_3 is hydrogen or methyl and R_4 is hydrogen.

3. (Twice Amended) The therapeutic compound of claim 1, wherein

R_3 is selected from the group consisting of methyl, ethyl, oxo, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, methylamino, aminomethyl, and methylphenyl; and